Australian ASX200 earnings preview CSL

CSL Limited (CSL) is Australia’s largest drugmaker, one of the world’s largest biotech companies, a leader in flu treatments and plasma protein therapies, and a leading provider of in-licensed vaccines. It reports its full-year numbers on Wednesday the 18th of August at 10 am.


COVID-19 continues to present challenges for CSL’s supply chains and the collection of plasma, an essential raw material used in the production of many of CSL’s therapies, which account for almost half of CSL’s sales.

CSL products are critical to sustaining patients’ lives, and because of this, its plasma collection centers and manufacturing facilities are classified as ‘essential services’ remaining operational during the pandemic.

The Covid-19 vaccine that CSL was working on with the University of Queensland was scrapped in December after it delivered misleading results. Following the cessation of the trials, CSL focused its attention on producing and accelerating the manufacture of the Oxford University/AstraZeneca COVID-19 vaccine. The first doses were dispatched at the end of March 2021. 

CSL is renowned as a quality company. However, it is trading only about 3% higher than it started in 2021, while the broader market is up over 15% year to date, partly explained by the increased costs associated with the collection of plasma. 

Some headwinds have begun to ease. A significant portion of CSL’s revenues is earned offshore in US dollars. A lower AUDUSD exchange rate is helpful to CSL’s earnings.

Additionally, CSL is believed to be a front runner to produce vaccines based on the mRNA science underpinning vaccines produced by Moderna and Pfizer instead of the AstraZeneca adenovirus-based vaccine. 

At its half-year earnings report, CSL said it expects FY NPAT to grow at between US$2.17 billion to $2.265 billion, implying growth of between 3% and 8%. Not overly exciting for a company trading on a price/earnings ratio of more than 44X FY 21s earnings.

Technically, the decline from the $342.75 high of February 2020 appears to be a countertrend after a stunning multi-year rally. Once the correction is complete, the uptrend is expected to resume. 

As such, we would consider buying CSL shares on a dip into support near $280, coming from the trendline from the March $267.53 low . Or on a sustained break above trend channel resistance $300/310ish, an indication the uptrend has resumed. 

CSL Daily Chart

Source Tradingview. The figures stated areas of the 17th of August 2021. Past performance is not a reliable indicator of future performance. This report does not contain and is not to be taken as having any financial product advice or financial product recommendation

Build your confidence risk free

More from ASX

Join our live webinars for the latest analysis and trading ideas. Register now

StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.

No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.

For further details see our full non-independent research disclaimer and quarterly summary.